WATERTOWN, Mass.--(EON: Enhanced Online News)--Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) today announced that it will present two posters at IDWeek 2013 that examine the potential of its lead antibiotic candidate, eravacycline, to treat serious multi-drug resistant (MDR) infections. The first will highlight positive results of a Phase 1 study assessing the bronchopulmonary disposition, safety, and tolerability of eravacycline in healthy men and women; this study represents the first clinical assessment of eravacycline for potential use in treating pneumonia. The second poster will provide the results of a study that examined the activity of eravacycline in vitro against multiple Gram-negative and Gram-positive pathogens to set quality-control limits for monitoring eravacycline activity in future testing programs.
“In addition, following this presentation of positive data from the Phase 1 bronchopulmonary study, we are looking forward to further assessing the potential of eravacycline to treat serious respiratory infections.”
“Tetraphase is excited to present new eravacycline data at IDWeek and to participate with other leaders in the fight against MDR infections by sharing fresh insights in dealing with the current global health crisis,” said Guy Macdonald, Tetraphase President and Chief Executive Officer. “In addition, following this presentation of positive data from the Phase 1 bronchopulmonary study, we are looking forward to further assessing the potential of eravacycline to treat serious respiratory infections.”
IDWeek is a joint meeting of The Infectious Disease Society of America (IDSA), the Society for Healthcare Epidemiology of America (SHEA), HIV Medicine Association (HIVMA), and the Pediatric Infectious Diseases Society (PIDS). IDWeek 2013 occurs from October 2-6, 2013 in San Francisco, California.
Details of the Tetraphase posters at IDWeek include:
- “A Phase 1, Open-Label, Safety and Pharmacokinetic Study to Assess Bronchopulmonary Disposition of Intravenous Eravacycline (TP-434) in Healthy Men and Women.” [Poster 708] Friday, October 4, 2013, 12:30 PM-2:00 PM. Poster Abstract Session: Antimicrobials: Novel Agents: (The Moscone Center: Poster Hall C)
- “Tier 2 Quality Control Study (CLSI M23-A3) for Microtiter Broth and Disk Diffusion Testing of Eravacycline (TP-434).” [Poster 751] Friday, October 4, 2013, 12:30 PM - 2:00 PM. Poster Abstract Session: Antimicrobials: Treatment of HAI and Resistant Infections: (The Moscone Center: Poster Hall C)
The Phase 1 study was funded in whole or in part with federal funds from the Biomedical Advanced Research and Development Authority (BARDA), Office of the Assistant Secretary for Preparedness and Response, Office of the Secretary, Department of Health and Human Services, under Contract No HHSO100201200002C.
About Tetraphase Pharmaceuticals, Inc.
Tetraphase is a clinical-stage biopharmaceutical company using its proprietary chemistry technology to create novel antibiotics for serious and life-threatening multi-drug resistant infections. Tetraphase's lead product candidate, eravacycline, is a fully synthetic tetracycline derivative being developed as a broad-spectrum intravenous and oral antibiotic for use as a first-line empiric monotherapy for the treatment of multi-drug resistant infections, including MDR Gram-negative infections.
Any statements in this press release about our future expectations, plans and prospects, including statements regarding our strategy, future operations, prospects, plans and objectives, and other statements containing the words "believes," "anticipates," "plans," "expects," and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: whether our cash resources will be sufficient to fund our continuing operations for the period anticipated; whether results obtained in preclinical studies and early clinical trials, such as the results referred to in this press release, will be indicative of results obtained in future clinical trials; whether eravacycline will advance into clinical trials and through the clinical trial process on a timely basis and receive approval from the FDA or equivalent foreign regulatory agencies; whether, if eravacycline obtains approval, it will be successfully distributed and marketed; and other factors discussed in the "Risk Factors" section of our quarterly report on Form 10-Q for the quarter ended June 30, 2013. The forward-looking statements included in this press release represent our views as of October 3, 2013. We anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these forward-looking statements at some point in the future, we specifically disclaim any obligation to do so.